Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free LEGN Stock Alerts

Legend Biotech (LEGN) Financials

Legend Biotech logo
$27.55 -1.05 (-3.67%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$27.13 -0.42 (-1.52%)
As of 05/15/2026 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Legend Biotech

Annual Income Statements for Legend Biotech

This table shows Legend Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.78 -102 -266 -404 -446 -518 -177 -297
Consolidated Net Income / (Loss)		 -2.78 -102 -266 -404 -446 -518 -177 -297
Net Income / (Loss) Continuing Operations		 -2.78 -102 -266 -404 -446 -518 -177 -297
Total Pre-Tax Income 		-1.62 -127 -308 -407 -446 -520 -158 -283
Total Operating Income		 -1.53 -135 -234 -403 -479 -520 -158 -283
Total Gross Profit		 63 60 70 60 31 63 540 474
Total Revenue		 63 60 75 69 117 315 800 904
Operating Revenue		 63 60 75 69 117 340 689 1,069
Other Revenue		 - - 0.00 - - -25 112 -165
Total Cost of Revenue		 0.00 0.22 4.56 9.13 86 252 261 431
Operating Cost of Revenue		 0.00 0.22 4.56 9.13 86 252 261 431
Total Operating Expenses		 65 194 305 463 510 583 698 756
Selling, General & Admin Expense		 3.93 32 73 150 174 201 284 342
Research & Development Expense		 61 162 232 313 336 382 414 415
Total Other Income / (Expense), net		 -0.08 7.24 -74 -7.10 33 0.00 0.00 0.00
Income Tax Expense		 1.17 -26 -42 -3.61 0.63 -1.90 19 14
Weighted Average Basic Shares Outstanding		 - - 266.01M 308.46M 330.13M 363.82M 367.30M 369.89M
Diluted Earnings per Share		 ($0.01) ($0.51) ($1.13) ($1.43) ($1.40) ($1.47) ($0.48) ($0.81)
Weighted Average Diluted Shares Outstanding		 - - 266.01M 308.46M 330.13M 363.82M 367.30M 369.89M
Weighted Average Basic & Diluted Shares Outstanding		 - - 266.01M 308.46M 330.13M 363.82M 367.30M 369.89M

Quarterly Income Statements for Legend Biotech

No quarterly income statements for Legend Biotech are available.

Annual Cash Flow Statements for Legend Biotech

This table details how cash moves in and out of Legend Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 208 -127 372 233 821 5,594 -991 5,366
Net Cash From Operating Activities		 308 -83 -223 8.38 433 4,973 -935 5,197
Net Cash From Continuing Operating Activities		 217 -79 -280 8.38 433 4,973 -935 5,197
Net Income / (Loss) Continuing Operations		 -1.62 -127 -308 0.00 0.00 0.00 0.00 0.00
Depreciation Expense		 1.67 5.20 9.74 13 10 11 21 9.40
Non-Cash Adjustments To Reconcile Net Income		 197 3.61 35 -142 420 4,962 -1,041 5,188
Net Cash From Investing Activities		 -102 -59 -24 -42 1.25 8.90 -14 0.00
Net Cash From Continuing Investing Activities		 -96 23 -30 -42 1.25 8.90 -14 0.00
Sale and/or Maturity of Investments		 - - - - 1.25 8.90 - 0.00
Net Cash From Financing Activities		 2.50 15 619 323 378 584 0.00 0.00
Net Cash From Continuing Financing Activities		 2.50 15 609 323 378 584 0.00 0.00
Issuance of Debt		 36 42 - 0.00 378 349 0.00 0.00
Issuance of Common Equity		 0.00 0.00 450 323 0.00 234 0.00 0.00
Effect of Exchange Rate Changes		 - - - - 9.16 28 -2.10 169
Cash Interest Received		 - - - 0.65 5.58 47 37 52

Quarterly Cash Flow Statements for Legend Biotech

No quarterly cash flow statements for Legend Biotech are available.

Annual Balance Sheets for Legend Biotech

This table presents Legend Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 1/1/2020 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 293 722 1,119 1,331 1,849 1,670 1,734
Total Current Assets		 115 532 950 1,099 1,498 1,284 1,247
Cash & Equivalents		 83 456 689 786 1,278 287 902
Accounts Receivable		 30 75 50 0.09 100 6.40 13
Inventories, net		 1.16 1.80 1.75 10 19 24 32
Prepaid Expenses		 - - 14 62 69 131 253
Plant, Property, & Equipment, net		 45 72 103 105 109 99 116
Plant, Property & Equipment, gross		 - - 103 105 109 99 116
Total Noncurrent Assets		 133 117 48 60 86 115 298
Other Noncurrent Operating Assets		 132 114 43 57 82 115 298
Total Liabilities & Shareholders' Equity		 444 1,320 1,119 1,331 1,849 1,670 1,734
Total Liabilities		 141 124 354 587 597 630 732
Total Current Liabilities		 94 116 229 298 216 278 636
Short-Term Debt		 0.00 0.00 - - - 0.00 319
Accounts Payable		 9.59 5.24 7.04 33 31 39 83
Current Deferred & Payable Income Tax Liabilities		 13 8.80 9.49 - - 21 19
Other Current Liabilities		 72 102 89 71 56 52 20
Total Noncurrent Liabilities		 47 8.76 124 289 381 352 95
Long-Term Debt		 - - 120 261 281 301 0.00
Capital Lease Obligations		 - - 1.59 20 44 45 87
Other Noncurrent Operating Liabilities		 5.06 4.51 0.40 0.23 48 6.10 8.00
Total Equity & Noncontrolling Interests		 303 1,196 766 744 1,251 1,041 1,002
Total Preferred & Common Equity		 303 1,196 766 744 1,251 1,041 1,002
Total Common Equity		 303 1,196 766 744 1,251 1,041 1,002
Common Stock		 0.02 0.03 0.03 0.03 0.04 0.10 0.10
Other Equity Adjustments		 303 1,196 766 744 1,251 1,041 1,002

Quarterly Balance Sheets for Legend Biotech

No quarterly balance sheets for Legend Biotech are available.

Annual Metrics And Ratios for Legend Biotech

This table displays calculated financial ratios and metrics derived from Legend Biotech's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - 369,886,369.00
DEI Adjusted Shares Outstanding		 - - - - - - - 369,886,369.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - -0.80
Growth Metrics		 - - - - - - - -
Profitability Metrics		 - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -1.07 -94 -164 -282 -335 -329 -232 -198
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -32.68% -20.90% -16.72% -14.05%
Earnings before Interest and Taxes (EBIT)		 -1.62 -127 -228 -410 -446 -520 -158 -283
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.07 -122 -218 -396 -433 -507 -135 -273
Valuation Ratios		 - - - - - - - -
Leverage & Solvency		 - - - - - - - -
Liquidity Ratios		 - - - - - - - -
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -162 -238 -251 -348 -447 -250 -522
Efficiency Ratios		 - - - - - - - -
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 68 142 111 124 241 259 583
Increase / (Decrease) in Invested Capital		 0.00 68 74 -31 13 117 18 325
Book Value per Share		 $0.00 $16.43 $4.49 $2.88 $2.41 $3.79 $2.86 $2.73
Tangible Book Value per Share		 $0.00 $16.40 $4.48 $2.86 $2.40 $3.78 $2.85 $2.73
Total Capital		 0.00 303 1,196 888 1,025 1,577 1,386 1,408
Total Debt		 0.00 0.00 0.00 122 281 325 346 406
Total Long-Term Debt		 0.00 0.00 0.00 122 281 325 346 87
Net Debt		 0.00 -83 -456 -567 -691 -953 59 -496
Capital Expenditures (CapEx)		 21 27 26 42 0.00 0.00 14 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -63 -39 32 -170 3.01 720 28
Debt-free Net Working Capital (DFNWC)		 0.00 20 417 721 801 1,281 1,006 930
Net Working Capital (NWC)		 0.00 20 417 721 801 1,281 1,006 611
Net Nonoperating Expense (NNE)		 1.71 7.40 102 121 111 189 -55 99
Net Nonoperating Obligations (NNO)		 0.00 -235 -1,053 -655 -620 -1,010 -781 -420
Total Depreciation and Amortization (D&A)		 1.68 5.26 9.93 14 13 13 23 9.40
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 266.01M 0.00 330.13M 363.82M 367.30M 369.89M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.48) ($0.81)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 266.01M 0.00 330.13M 363.82M 367.30M 369.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 266.01M 0.00 330.13M 363.82M 367.30M 369.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.07 -94 -164 -282 -335 -329 -229 -198
Debt Service Ratios		 - - - - - - - -
Payout Ratios		 - - - - - - - -

Quarterly Metrics And Ratios for Legend Biotech

No quarterly metrics and ratios for Legend Biotech are available.


Financials Breakdown Chart

Legend Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Legend Biotech's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Legend Biotech's net income appears to be on an upward trend, with a most recent value of -$296.80 million in 2025, rising from -$2.78 million in 2018. The previous period was -$177 million in 2024. Find out what analysts predict for Legend Biotech in the coming months.

Legend Biotech's total operating income in 2025 was -$282.60 million, based on the following breakdown:
  • Total Gross Profit: $473.70 million
  • Total Operating Expenses: $756.30 million

Over the last 7 years, Legend Biotech's total revenue changed from $63.03 million in 2018 to $904.20 million in 2025, a change of 1,334.5%.

Legend Biotech's total liabilities were at $731.60 million at the end of 2025, a 16.2% increase from 2024, and a 417.8% increase since 2019.

In the past 6 years, Legend Biotech's cash and equivalents has ranged from $83.36 million in 2019 to $1.28 billion in 2023, and is currently $901.90 million as of their latest financial filing in 2025.

Over the last 7 years, Legend Biotech's book value per share changed from 0.00 in 2018 to 2.73 in 2025, a change of 272.8%.


Related Companies

Financial statements for NASDAQ:LEGN last updated on 3/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
SpaceX Goes Public. Here's What Happens To Your IRA.
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel